Cellergy Bio
1 known investors
Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.